Directorio

We are doing this study to see if radiation and chemotherapy can be done instead of an extensive surgical removal of the groin lymph nodes for patients with vulvar cancer whose disease has spread to the sentinel node. We are doing this study because we want to find out if this approach is better or worse than the usual approach for vulvar cancer.

This study has three groups. In each group, people receive medicines used to treat this type of cancer through a vein every three weeks for several treatment cycles. In the first group, people receive common cancer medicines along with another medicine called pembrolizumab. After this part, they continue with pembrolizumab alone for a longer time, with treatments given every six weeks for up to about two years. In another group, people receive a study medicine called bevacizumab together with standard cancer treatments. These medicines are also given through a vein during regular treatment cycles. The study is designed to compare these different treatment plans to see which works best and is safest for patients.

To join this study, patients must have bladder cancer proven by a lab test. The cancer must be in stages called cT2 to T3 and must not have spread to the lymph nodes or other parts of the body. Before joining, patients need a surgery called TURBT to remove as much of the tumor as possible. Patients also need scans of the chest, belly, and pelvis using CT or MRI to make sure the cancer has not spread. If any lymph nodes look big, they must be tested to show there is no cancer. Patients cannot have cancer that has spread or certain types of bladder cancer. Patients must be 18 or older. They cannot have had radiation to the pelvis before. If they had other treatments, any side effects must be mostly gone.

We are doing this study to find out if stereotactic body radiation therapy (SBRT) might be beneficial for people with non-small cell lung cancer (NSCLC). We want to compare the outcomes between the standard treatment for NSCLC and the standard treatment with the addition of SBRT.

We are doing this study to find the most effective, safe dose of an experimental drug called NX-5948 (the study drug). We want to know how well this study drug works in people with B-cell lymphomas.

We are doing this study to find the most effective, safe dose of an experimental drug called NVL-655 (the study drug). We want to know how well the study drug works compared to alectinib, which is a standard treatment for NSCLC.

This study has three parts, called screening, treatment, and follow up. During screening, doctors will check if a person can join the study. If eligible, participants will take a study medicine called NX 5948 by mouth once every day. The medicine is taken in cycles that last 28 days. People will keep taking the medicine as long as it is helping and side effects are manageable. Treatment may stop if the cancer gets worse, side effects become too severe, or the study ends. After treatment stops, participants will continue to be followed by the study team so doctors can check their health over time.

In this study, people will be placed into one of two groups by chance. One group will have a procedure to remove the kidney stone within about 90 days of joining the study. The other group will be closely monitored without having the stone removed right away. Everyone in the study will be followed for two years. Participants will have regular clinic visits, at least once each year, and will complete surveys every three months about any symptoms they have. Researchers want to learn which approach is better for people who have kidney stones that are not causing pain or other problems.